<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03404024</url>
  </required_header>
  <id_info>
    <org_study_id>VMCAD-002</org_study_id>
    <nct_id>NCT03404024</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Gene Therapy for Acute Myocardial Infarction in Korea</brief_title>
  <official_title>A Phase II, Multicenter, Adaptive-design Study to Assess the Safety and Efficacy of VM202RY Injected Via Percutaneous Transendocardial Route in Subjects With Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViroMed Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ViroMed Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and clinical efficacy of VM202RY injected
      via transendocardial route using C-Cathez® catheter (Celyad, S.A., Belgium) in subjects with
      AMI.

        -  Stage 1: Evaluation of safety and tolerability of VM202RY injection

        -  Stage 2: Evaluation of safety and efficacy of VM202RY injection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ischemic heart disease, a condition in which narrowed or blocked coronary arteries lead to
      ischemia in myocardium, is a group of disease that include: angina and myocardial infarction.

      Acute myocardial infarction (AMI) predicts rapid progression of necrosis. AMI is a serious
      health condition that it's mortality rate is about 30% and also more likely to have a higher
      incidence of cardiac dysrhythmia or ventricular aneurysm.

      Therapeutic angiogenesis is promising approach for the treatment of cardiovascular disease.
      66 to 75% of coronary artery disease patients have insufficient coronary collaterals and 30%
      of myocardial infarction patients display inadequate myocardial perfusion although there are
      procedures like percutaneous coronary intervention or coronary artery bypass graft surgery.

      In phase I study for ischemic heart disease, VM202RY appeared to have improved regional
      myocardial perfusion and wall thickness of the diastolic and systolic phases in the injected
      region. These results suggest that VM202RY improves the myocardial perfusion and inhibits
      cardiac remodeling in ischemic heart disease patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2018</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stage 1: MTD (maximum tolerated dose)</measure>
    <time_frame>6 months</time_frame>
    <description>• MTD is defined as the dose level below the dose at which ≥ 33% of participants experienced DLT (dose limiting toxicity). The DLT assessment will be conducted on day 14. Toxicities more severe than grade 3 on the WHO toxicity scale will be designated as DLT. The dose where severe adverse events occur according to the Spilker classification will also be designated as DLT. The assessment will be conducted from the lowest dose to higher doses incrementally. MTD will be measured in milligrams (mg).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: LVEF (left ventricular ejection fraction) measured by cardiac MRI</measure>
    <time_frame>6 months</time_frame>
    <description>• The change in LVEF measured by cardiac MRI in VM202RY and placebo will be compared at 6 months after the treatment of VM202RY or Placebo by transendocardial injections using C-CATHez® catheter. LVEF will be measured in percentage (%).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular diameter (cardiac MRI)</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>The change in diameter of left ventricle will be measured in millimeters (mm), at months 3 and 6 using cardiac MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular diameter (TTE)</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>The change in diameter of left ventricle will be measured in millimeters (mm), at months 3 and 6 using TTE (transthoracic echocardiogram).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular volume (cardiac MRI)</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>The change in volume of left ventricle will be measured in milliliters (mL), at months 3 and 6 using cardiac MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular volume (TTE)</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>The change in volume of left ventricle will be measured in milliliters (mL), at months 3 and 6 using TTE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiac output (cardiac MRI)</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>The change in cardiac output will be measured in liters per minute (L/min), at months 3 and 6 using cardiac MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiac output (TTE)</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>The change in cardiac output will be measured in liters per minute (L/min), at months 3 and 6 using TTE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LVEF (cardiac MRI)</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>The change in left ventricular ejection fraction will be measured in percentage (%), at months 3 and 6 using cardiac MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LVEF (TTE)</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>The change in left ventricular ejection fraction will be measured in percentage (%), at months 3 and 6 using TTE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in wall motion score index (cardiac MRI)</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>The wall motion score index will be measured at months 3 and 6 using cardiac MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in wall motion score index (TTE)</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>The wall motion score index will be measured at months 3 and 6 using TTE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in myocardial wall thickness (cardiac MRI)</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>The change in myocardial wall thickness of the investigational-product or placebo injected area will be measured in millimeters (mm) at months 3 and 6 using cardiac MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in extent of late enhancement of gadolinium (cardiac MRI)</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>The change in extent of late enhancement of gadolinium will be measured at months 3 and 6 using cardiac MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in rest perfusion (cardiac MRI)</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>The change in rest perfusion will be measured in percentage (%) at months 3 and 6 using cardiac MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in rest perfusion (myocardial SPECT)</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>The change in rest perfusion will be measured in percentage (%) at months 3 and 6 using myocardial SPECT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in stress perfusion (cardiac MRI)</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>The change in stress perfusion will be measured in percentage (%) at months 3 and 6 using cardiac MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in stress perfusion (myocardial SPECT)</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>The change in stress perfusion will be measured in percentage (%) at months 3 and 6 using myocardial SPECT.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Stage 1-Low dose VM202RY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive total 1mg of VM202RY. (4 sites of 0.25mg/0.5 mL VM202RY)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1-Middle dose VM202RY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive total 2mg of VM202RY. (8 sites of 0.25mg/0.5 mL VM202RY)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1-High dose VM202RY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive total 3mg of VM202RY. (12 sites of 0.25mg/0.5 mL VM202RY)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in this group will receive 6mL of VM202RY vehicle. (12 sites of 0.5mL 0.9% NaCl, 1.1% sucrose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2-Low dose VM202RY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive total 6mL of VM202RY and VM202RY vehicle. (The dose of VM202RY can be one of the three candidate-0.5mg VM202RY/1mg VM202RY/1.5mg VM202RY based on the tolerated dose result from Stage 1.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2-High dose VM202RY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive total 6mL of VM202RY and VM202RY vehicle. (The dose of VM202RY can be one of the three candidate-1mg VM202RY/2mg VM202RY/3mg VM202RY based on the tolerated dose result from Stage 1.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Stage 1-Low dose VM202RY</intervention_name>
    <description>Day 0: 1mg of VM202RY (4 sites of 0.25mg/0.5mL VM202RY)</description>
    <arm_group_label>Stage 1-Low dose VM202RY</arm_group_label>
    <other_name>DNA Plasmid</other_name>
    <other_name>Hepatocyte growth factor (HGF)-X7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Stage 1-Middle dose VM202RY</intervention_name>
    <description>Day 0: 2mg of VM202RY (8 sites of 0.25mg/0.5mL VM202RY)</description>
    <arm_group_label>Stage 1-Middle dose VM202RY</arm_group_label>
    <other_name>DNA Plasmid</other_name>
    <other_name>HGF-X7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Stage 1-High dose VM202RY</intervention_name>
    <description>Day 0: 3mg of VM202RY (12 sites of 0.25mg/0.5mL VM202RY)</description>
    <arm_group_label>Stage 1-High dose VM202RY</arm_group_label>
    <other_name>DNA Plasmid</other_name>
    <other_name>HGF-X7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stage 2-Placebo</intervention_name>
    <description>Day 0: 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl)</description>
    <arm_group_label>Stage 2-Placebo</arm_group_label>
    <other_name>VM202RY vehicle</other_name>
    <other_name>Sodium chloride, sucrose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Stage 2-Low dose VM202RY</intervention_name>
    <description>Day 0: 6mL of VM202RY and VM202RY vehicle (total 12 site injections, low dose candidate-0.5mg VM202RY, 1mg VM202RY, 1.5mg VM202RY)</description>
    <arm_group_label>Stage 2-Low dose VM202RY</arm_group_label>
    <other_name>DNA plasmid</other_name>
    <other_name>HGF-X7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Stage 2-High dose VM202RY</intervention_name>
    <description>Day 0: 6mL of VM202RY and VM202RY vehicle (total 12 site injections, high dose candidate-1mg VM202RY, 2mg VM202RY, 3mg VM202RY)</description>
    <arm_group_label>Stage 2-High dose VM202RY</arm_group_label>
    <other_name>DNA Plasmid</other_name>
    <other_name>HGF-X7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>C-Cathez® Catheter</intervention_name>
    <description>Day 0 (Stage 1-Low dose VM202RY): 1mg of VM202RY (4 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-Middle dose VM202RY): 2mg of VM202RY (8 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-High dose VM202RY): 3mg of VM202RY (12 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 2-Placebo): 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl) Day 0 (Stage 2-Low dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, low dose candidate-0.5mg VM202RY, 1mg VM202RY, 1.5mg VM202RY) Day 0 (Stage 2-High dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, high dose candidate-1mg VM202RY, 2mg VM202RY, 3mg VM202RY)</description>
    <arm_group_label>Stage 1-Low dose VM202RY</arm_group_label>
    <arm_group_label>Stage 1-Middle dose VM202RY</arm_group_label>
    <arm_group_label>Stage 1-High dose VM202RY</arm_group_label>
    <arm_group_label>Stage 2-Placebo</arm_group_label>
    <arm_group_label>Stage 2-Low dose VM202RY</arm_group_label>
    <arm_group_label>Stage 2-High dose VM202RY</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 19 years to ≤ 75 years

          2. Patients who underwent percutaneous coronary intervention (PCI) for the anterior wall
             infarction of left ventricle and had the elapsed time of 30 ± 2 days from the PCI,
             regardless of success or failure of myocardial revascularization in the anterior wall

          3. Patients with &gt; 20% to ≤ 45% of left ventricular ejection fraction via trans-thoracic
             echocardiography within 7 days prior to the study drug or placebo injection

          4. Left ventricular wall thickness ≥ 8 mm via trans-thoracic echocardiography

          5. If female of childbearing potential, negative urine pregnancy test at screening and
             using acceptable method of birth control during the study; if male, using barrier
             method of birth control during study

          6. Be capable of understanding and complying with the protocol and signing the informed
             consent document prior to being subjected to any study related procedures.

        Exclusion Criteria:

          1. Severe systolic heart failure, NYHA Class III or IV

          2. New York Heart Association (NYHA) functional class IV

          3. History of recurrent ventricular tachycardia or cariogenic shock following PCI

          4. Stroke or transient ischemic attack (TIA) within 180 days

          5. Uncontrolled hypertension defined as systolic blood pressure ≥ 180 mmHg or diastolic ≥
             110 mmHg at screening and/or on the day of study drug or placebo injection

          6. Sustained ventricular tachyarrhythmia or recurrent ventricular tachycardia

          7. Implantation of automatic implantable cardioverter defibrillator (AICD)

          8. On extracorporeal membrane oxygenator (ECMO)

          9. History of ventricular fibrillation after PCI

         10. Permanent pacemaker implantation (temporary pacemaker may be enrolled)

         11. Subjects with aortic stenosis of moderate or greater degree, or with prosthetic aortic
             valve who may not be appropriate to use the C-CATHez® catheter due to the risk of
             injury during the interventional procedure through the valve

         12. Atherosclerotic or other disease of the aorto-iliac system that would impede the safe
             passage of the C-CATHez®

         13. Subjects with any serious comorbidities that the investigators deemed to be
             inappropriate to be enrolled

         14. Patients with a recent history (&lt; 5 years) of, or new screening finding of malignant
             neoplasm except basal cell carcinoma or squamous cell carcinoma of the skin (if
             excised and no evidence of recurrence); patients with family history of colon cancer
             in any first degree relative are excluded unless they have undergone a colonoscopy in
             the last 12 months with negative findings

         15. Elevated prostate-specific antigen (PSA) despite not having prostate cancer history

         16. Ophthalmologic conditions pertinent to proliferative retinopathy or conditions that
             preclude standard ophthalmologic examination Diagnosis of proliferative retinopathy or
             conditions that preclude standard ophthalmologic examination

         17. Subjects currently receiving immunosuppressive medications, chemotherapy, or radiation
             therapy

         18. Active infectious disease and/or positive Human Immunodeficiency Virus (HIV) or Human
             T-Cell lymphotropic viruses (HTLV) at screening

         19. Active Hepatitis B or C infection as determined by Hepatitis B surface antibody
             (HBsAb), Hepatitis B core antibody (Immunoglobulin G and Immunoglobulin M; HBcAb),
             Hepatitis B surface antigen (HBsAg) and Hepatitis C antibodies (Anti-HCV) at screening

         20. Specific laboratory values at screening including

               -  Hemoglobin ≤ 9.0 g/dL, white blood cell (WBC) &lt; 3,000 cells/μl, platelet count &lt;
                  75,000/mm3

               -  Creatinine &gt; 2.0 mg/dL

               -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) &gt; 3 x
                  upper limit of normal (ULN)

               -  Any other clinically significant lab abnormality which in the opinion of the
                  investigator should be exclusionary

         21. Subjects requiring &gt; 100 mg daily of acetylsalicylic acid (ASA); subjects may be
             enrolled if willing/able to switch to ≤ 100 mg daily of ASA or to another medication

         22. Subjects regularly taking cyclooxygenase (COX)-2 inhibiting drug(s) or non-specific
             COX-1/COX-2 inhibiting drugs, or high dose steroids (except inhaled steroids);
             subjects may be enrolled if willing/able to undergo medication wash-out prior to the
             first dosing and to refrain from taking these drugs for the duration of the study, and
             also if the subject is temporarily taking NSAID (non-steroidal anti-inflammatory drug)
             temporarily (≤ 7 days)

         23. Patients that have undergone enhanced external pulsation (EECP) treatment within the
             last 6 months

         24. Pregnancy or lactation

         25. Severe comorbidity associated with a reduction of life expectancy of less than 1 year

         26. Exposure to any previous experimental angiogenic therapy and/or myocardial laser
             therapy; or therapy with another investigational drug within 180 days of enrollment or
             participation in any concurrent study that may confound the results of this study

         27. Major psychiatric disorder in the past 6 months

         28. Known drug or alcohol dependence or any other factors which will interfere with the
             study conduct or interpretation of the results or who in the opinion of the
             investigator are not suitable to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wook Bum Pyun, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ewha Womans University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hong Sik Yoon, PharmD</last_name>
    <phone>02-2102-7200</phone>
    <email>hsyoon@viromed.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>GangNeung Asan Hospital</name>
      <address>
        <city>Gangneung</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sang-Yong Yoo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ju Han Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wook Bum Pyun, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KyungHee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Soo-Joong Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Myoung-Ho Yoon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2017</study_first_submitted>
  <study_first_submitted_qc>January 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2018</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

